SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following FDA approval for its oral Wegovy pill, a significant development in the weight-loss drug market. The community is actively discussing the convenience of a pill over injections and its potential to capture substantial market share, intensifying competition with Eli Lilly. Many are debating whether this breakthrough will lead to sustained gains and a re-evaluation of the company's valuation.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is trending due to its explosive post-IPO gains, fueled by its low public float and intense speculative interest in the aerospace sector. Community chatter is highly polarized, with many celebrating its "parabolic" ascent and comparing it to past runners, while others caution it's an overhyped "pump and dump" given its limited operational history and fundamental concerns. This stark debate highlights the stock's significant volatility and high investor attention.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent exploration drill results indicating high-grade silver in its Vortex system, significantly expanding the perceived value of its vast deposits. This news is driving community discussion around potential for a substantial short squeeze, robust institutional interest from major investors like Eric Sprott, and the broader tailwind of increasing gold and silver prices. While many are optimistic about the company's long-term prospects as a debt-free entity with considerable resources, some express caution regarding its lack of current revenue and highly elevated technical indicators.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending amidst heightened activity in the oral obesity drug market, following a competitor's oral GLP-1 approval which the community views as category-validating. Investors are actively comparing VKTX's oral VK2735, citing its strong efficacy and superior tolerability profile in early trials as a potential "best in class" contender. Discussions center on the expanding market opportunity, VKTX's pipeline progression, and the anticipation of potential partnerships or acquisitions.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is generating significant buzz due to its amended, all-cash takeover offer for Warner Bros. Discovery, now fortified by a substantial personal guarantee from Larry Ellison. This move has ignited community discussion, with many viewing PSKY's bid as a superior path to shareholder value compared to rival proposals, potentially impacting the broader media streaming market.

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Niagen Bioscience Inc.

Niagen Bioscience (NAGE) is a focal point of market conversation, driven by anticipation for results from its NOPARK trial in Parkinson's disease and other clinical studies, along with expanding Niagen+ offerings. The community is actively debating the company's significant growth potential, eyeing strategic pharmaceutical partnerships and the impact of strong financial performance on its perceived undervaluation in the burgeoning NAD+ market.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is seeing heightened discussion following its $1.5 billion At-The-Market offering, which is fueling intense debate over its valuation and future as an SMR developer. Bulls emphasize the company's potential to power AI data centers, recent DOE backing, and anticipated plutonium awards, viewing it as a generational energy shift. Conversely, bears aggressively highlight its zero revenue, continuous dilution, regulatory hurdles, and high market capitalization, frequently labeling it a speculative bubble.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust ($GBTC) is trending amidst fierce community debate over Bitcoin's price trajectory. While some warn of an impending 'crypto winter' and significant downturns citing historical cycles and institutional 'manipulation,' others see current price action as a buying opportunity, anticipating a parabolic rally and new highs for Bitcoin as a hedge against broader economic trends.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending due to its recent acquisition of Melt Pharmaceuticals and the strategic launch of its HarrowAccess For All platform, aiming to streamline patient access and boost its competitive edge in ophthalmic care. The investor community is highly optimistic about Harrow's long-term revenue growth driven by key products like Vevye and Iheezo, with many anticipating ambitious targets and a potential short squeeze ahead of its upcoming Investor Day.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is trending amidst community speculation regarding a potential acquisition or significant pipeline news, particularly concerning its SG-001 program, following a notable period without new company announcements. Despite underlying optimism about the company's strong fundamentals and future earnings growth driven by product demand and yield enhancements, investors are actively discussing perceived stock volatility and a disconnect between valuation and performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
